Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice vs single-dose aprepitant injection for prevention of chemotherapy-induced nausea and vomiting
ChiCTR2500104533Phase 4Completed
- Sponsor
- Jiangsu University Affiliated Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Jiangsu University Affiliated Hospital. Primary endpoint: Duration of complete remission. Started Jun 2025; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2500104533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104533.